Castle Biosciences

The approvals allow the company to offer its PCR-based expression profile cancer risk tests in the state.

The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.

Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.

The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.

The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.

The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.

The financing will go toward commercial and clinical activities to increase adoption of the company's DecisionDx-Melanoma test.

The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.